| 1 Perou CM.Sorlie T.Eisen MB,et al.Molecular portraits of human breast tumours [J].Nature,2000,406(6797):747-752.
2 Rouzier R,Perou CM,Symmans WF,et al.Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J].Clin Cancer Res,2005,11 (16):5678-85.
3 Calza S,Hall P,Auer G,et al.Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J].Breast Cancer Res,2006,8(4);34- 42.
4 Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res, 2004,10(16):5367-74.
5 Rakha EA,EI-Sayed ME,Green AR.Prognostic markers in triple-negative breast cancer[J].Cancer,2007,109(1):25-32.
6 Bauer KR,Brown M,Cress RD,et al.Descriptive analysis of estrogen receptor (ER) -negative,progesterone receptor(PR)-negative,and HER-2 negative invasive breast cancer,the so-called triple-negative phenotype;A population-based study from the California Cancer Registry[J].Cancer,2007,109(9):1721-28.
7 Dent R,Trudeau MtPritchard KI,et al.Triple-negative breast cancer;Clinical features and patterns of recurrence[J].Clin Cancer Res,2007,13(15):4429-34.
8 livasy CA,Karacs G,Nanda R,et aL Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma[J].Mod,Pathol,2006,19(2):264-271.
9 Tischkowitz M,Brunet JS,Begin LR,et al.Use of immunohistochemical markers can refine prognosis in triple negative breast cancer[J],BMC Cancer,2007,7: 134-144.
10 Haffty BG,Yang Q,Reiss M,et al.Locoregional relapse and distant metastasis in conservatively managed triple negative early stage breast cancer[J].J Clin On- col,2006,24(36):5652-57.
11 Turner N,Tutt A,Ashworth A.Hallmarks of“BRCAness”in sporadic cancen [J].Nature Reviews Cancer,2004,4(10):814-819.
12 Liedtke C,Mazouni C,Hess KR,et al Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer[J].J Clin Oncol, 2008,26(8):1275-81.
13 Carey LA,Dees EC,Sawyer L,et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes[J].Clin Cancer Res,2007,13(8): 2329-34.
14 Torrisi R,Balduzzi A,Ghisini R,et al.Tailored preoperative treatment of locally advanced triple negative(hormone receptor negative and HER2 negative) breast cancer with epirubicin,cisplatin,and infusional fluorouracil followed by weekly paclitaxel[J].Cancer Chemotherapy and Pharmacology,2008,62(4):667-672.
15 Garber JE,Richardson A,Harris LN,et al.Neo-adjuvant cisplatin(CDDP) in triple -negative breast cancer(BC)[J].Breast Cancer Res Treat,2007,100(1): 149-158.
16 Corkery B,O'Donovan N,Clynes M,et al Epidermal growth factor receptor(EGFR) inhibition in triple-negative breast cancer[J].J Clin Oncol,2007,25(18): 14071-82.
17 Roussidis AE.Theocharis AD,Tzanakakis GN,et al.The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer[J]. Curr Med Chem,2007,14(7):735-743.
18 Chow LW,Yip AY,Loo WT,et al.Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer[J],Cancer Lett,2008, 262(2):232-238.
19 Burstein HJ.Elias AD.Rugo HS.et al.PhaseⅡstudy of sunitinib malate,an oral multitargeted tyrosine kinase inhibitor,in patients with metastatic breast cancer previously treated with an anthracycline and a taxane[J].J Clin Oncol,2008,26 (11):1810-16.
20 Huang F,Reeves K,Han X,et al.Identification of candidate molecular markets predicting sensitivity in solid tumors to dasatinib;Rationale for patient selection [J].Cancer Res,2007,67(5):2226-38.
21 Finn RS,Dering J,Cinther C,et aL Dasatinib,an orally active small molecule inhibitor of both the sic and abl kinases,selectively inhibits growth of basal-type/“triple- negative”breast cancer cell lines growing in vitro[J].Breast Cancer Res Treat,2007,105(3):319-326.
22 Kyndi M,Sorensen FB,Knudsen H,et al.Estrogen receptor,progesterone receptor,HER-2,and response to postrnastectomy radiotherapy in high-rish hreast cancer:the Danish Breast Cancer Cooperative Group[J].J Clin Oncol,2008,26,(9):1419-26. |
